Abstract
Pancreatic cancer is a devastating malignancy with a median survival of less than one year. The exceedingly poor prognosis for metastatic pancreatic cancer patients remains a significant unmet medical need and is an opportunity for development of novel therapeutic approaches incorporating gene therapy strategies. Barriers exist preventing effective gene therapy including low transfection efficiency, poor tissue penetrance as well as non-specific delivery. However, one specific strategy using synthetic short interfering RNA fragments holds great potential and recently demonstrated successful systemic delivery using a transferrin (Tf)-targeted cyclodextrin-based polymer nanoparticle. Various nanoparticle formulations are currently being optimized for systemic gene therapy approaches. In this review, we highlight the rapidly progressing field of gene therapy strategies that have the potential to enhance the care of patients with devastating malignancies such as pancreatic cancer and focus on systemic delivery strategies to overcome remaining hurdles limiting widespread clinical applications.
Keywords: Gene therapy, Short interfering RNA fragment, Nanoparticle, Pancreatic cancer.
Current Cancer Therapy Reviews
Title:Optimizing Gene Silencing Strategies for Pancreatic Cancer
Volume: 9 Issue: 2
Author(s): Ernest Ramsay Camp, Katie Hurst, Cindy Wang, David J. Cole and Dennis K. Watson
Affiliation:
Keywords: Gene therapy, Short interfering RNA fragment, Nanoparticle, Pancreatic cancer.
Abstract: Pancreatic cancer is a devastating malignancy with a median survival of less than one year. The exceedingly poor prognosis for metastatic pancreatic cancer patients remains a significant unmet medical need and is an opportunity for development of novel therapeutic approaches incorporating gene therapy strategies. Barriers exist preventing effective gene therapy including low transfection efficiency, poor tissue penetrance as well as non-specific delivery. However, one specific strategy using synthetic short interfering RNA fragments holds great potential and recently demonstrated successful systemic delivery using a transferrin (Tf)-targeted cyclodextrin-based polymer nanoparticle. Various nanoparticle formulations are currently being optimized for systemic gene therapy approaches. In this review, we highlight the rapidly progressing field of gene therapy strategies that have the potential to enhance the care of patients with devastating malignancies such as pancreatic cancer and focus on systemic delivery strategies to overcome remaining hurdles limiting widespread clinical applications.
Export Options
About this article
Cite this article as:
Camp Ramsay Ernest, Hurst Katie, Wang Cindy, Cole David J. and Watson K. Dennis, Optimizing Gene Silencing Strategies for Pancreatic Cancer, Current Cancer Therapy Reviews 2013; 9 (2) . https://dx.doi.org/10.2174/1573394711309020004
DOI https://dx.doi.org/10.2174/1573394711309020004 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Regulation of miRNAs in Inflammation-Related Carcinogenesis
Current Pharmaceutical Design Novel Mechanisms of Anticancer Activities of Green Tea Component Epigallocatechin- 3-Gallate
Anti-Cancer Agents in Medicinal Chemistry Fiber Optic Sensors for Biomedical Applications
Current Analytical Chemistry Azelaic Acid: A Promising Agent for Dermatological Applications
Current Drug Therapy Signaling Epicenters: The Role of Caveolae and Caveolins in Volatile Anesthetic Induced Cardiac Protection
Current Pharmaceutical Design Oncotarget Strategies For Herpes Simplex Virus-1
Current Gene Therapy Naturally Occurring and Related Synthetic Cannabinoids and their Potential Therapeutic Applications
Recent Patents on CNS Drug Discovery (Discontinued) Membrane Localization of Estrogen Receptors
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Recent Developments in Targeting Breast Cancer Stem Cells
Recent Patents on Regenerative Medicine Positron Emission Tomography in the Diagnosis and Treatment Management of Tuberculosis
Current Pharmaceutical Design Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Endocrine, Metabolic & Immune Disorders - Drug Targets Apoptosis-related BCL2-family Members: Key Players in Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry A Molecular Link Between Diabetes and Breast Cancer: Therapeutic Potential of Repurposing Incretin-based Therapies for Breast Cancer
Current Cancer Drug Targets Mast Cells in Allergic and Inflammatory Diseases
Current Pharmaceutical Design Redox Regulation in the Base Excision Repair Pathway: Old and New Players as Cancer Therapeutic Targets
Current Medicinal Chemistry Adjuvant Zoledronic Acid Reduces Disease Recurrence in Breast Cancer: Antitumor Effects on the Seed and the Soil
Current Cancer Therapy Reviews Synthesis and Biological Evaluation of 2-, 3-, and 4-Acylaminocinnamyl-Nhydroxyamides as Novel Synthetic HDAC Inhibitors
Medicinal Chemistry Tumor Angiogenesis: A Potential Target In Cancer Control by Phytochemicals
Current Cancer Drug Targets Nano-Chitosan Particles in Anticancer Drug Delivery: An Up-to-Date Review
Mini-Reviews in Medicinal Chemistry Advances in Anticancer Antibody-Drug Conjugates and Immunotoxins
Recent Patents on Anti-Cancer Drug Discovery